» Articles » PMID: 12016098

Effect of Theophylline on Induced Sputum Inflammatory Indices and Neutrophil Chemotaxis in Chronic Obstructive Pulmonary Disease

Overview
Specialty Critical Care
Date 2002 May 23
PMID 12016098
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by a neutrophilic airway inflammation that can be demonstrated by examination of induced sputum. Theophylline has antiinflammatory effects in asthma, and in the present study we investigated whether a similar effect occurs in COPD patients treated with low doses of theophylline. Twenty-five patients with COPD were treated with theophylline (plasma level of 9-11 mg/L) for 4 weeks in a placebo-controlled, randomized, double-blind crossover study. Theophylline was well tolerated. Induced sputum inflammatory cells, neutrophils, interleukin-8, myeloperoxidase, and lactoferrin were all significantly reduced by about 22% by theophylline. Neutrophils from subjects treated with theophylline showed reduced chemotaxis to N-formyl-met-leu-phe (approximately 28%) and interleukin-8 (approximately 60%). Neutrophils from a healthy donor showed reduced chemotaxis (approximately 30%) to induced sputum samples obtained during theophylline treatment. These results suggest that theophylline has antiinflammatory properties that may be useful in the long-term treatment of COPD.

Citing Articles

PDE4 Inhibitors and their Potential Combinations for the Treatment of Chronic Obstructive Pulmonary Disease: A Narrative Review.

Kumar R, Khan M, Panwar A, Vashist B, Rai S, Kumar A Open Respir Med J. 2025; 18():e18743064340418.

PMID: 39839967 PMC: 11748061. DOI: 10.2174/0118743064340418241021095046.


Effects of doxofylline as an adjuvant on severe exacerbation and long-term prognosis for COPD with different clinical subtypes.

Chen M, He W, Huang D, Jia H, Zhong Z, Li N Clin Respir J. 2023; 17(9):851-864.

PMID: 37562435 PMC: 10500324. DOI: 10.1111/crj.13670.


One stone two birds: anti-inflammatory bronchodilators as a potential pharmacological strategy for COVID-19.

Yu Y, Fang B, Yang X, Zheng Y Front Pharmacol. 2023; 14:1185076.

PMID: 37214443 PMC: 10192734. DOI: 10.3389/fphar.2023.1185076.


Airway microbiome-immune crosstalk in chronic obstructive pulmonary disease.

Kayongo A, Robertson N, Siddharthan T, Ntayi M, Ndawula J, Sande O Front Immunol. 2023; 13:1085551.

PMID: 36741369 PMC: 9890194. DOI: 10.3389/fimmu.2022.1085551.


Theophylline: Old Drug in a New Light, Application in COVID-19 through Computational Studies.

Montano L, Sommer B, Gomez-Verjan J, Morales-Paoli G, Ramirez-Salinas G, Solis-Chagoyan H Int J Mol Sci. 2022; 23(8).

PMID: 35456985 PMC: 9030606. DOI: 10.3390/ijms23084167.